Results 81 to 90 of about 11,782,455 (235)

Incidental finding of non-alcoholic steatohepatitis-cirrhosis

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2022
A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease.
Therese Adrian   +3 more
doaj   +1 more source

Non-alcoholic steatohepatitis and liver transplantation

open access: yes, 2016
Non-alcoholic steatohepatitis is a growing liver-related health problem. In Europe, non-alcoholic fatty liver disease is the most usual reason of chronic liver illness while steatohepatitis, its progressive form, affects 1% of Europeans and North ...
Andreone, Pietro   +6 more
core   +1 more source

ADISSP Drives Metabolic Reprogramming and Immune Suppression to Regulate Hepatocellular Carcinoma Progression and Immunotherapy Sensitivity

open access: yesAdvanced Science, EarlyView.
In HCC, ADISSP sustains IKKβ/NF‐κB signaling by inhibiting PPP1CA‐mediated IKKβ dephosphorylation, thereby inducing the expressions of SLC16A3 and CCL20. SLC16A3‐driven lactate remodeling promotes glycolysis, ferroptosis resistance, and M2 macrophage polarization, whereas CCL20 facilitates macrophage recruitment.
Tuan‐Song Zhang   +10 more
wiley   +1 more source

Src kinase as a potential therapeutic target in non‐alcoholic and alcoholic steatohepatitis

open access: yesClinical and Translational Discovery, 2022
Non‐alcoholic steatohepatitis (NASH) and alcohol‐associated steatohepatitis (ASH) are the major cause of liver‐related mortality with limited therapeutic options available.
Dhadhang Wahyu Kurniawan   +13 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić   +8 more
wiley   +1 more source

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models

open access: yesJournal of Cachexia, Sarcopenia and Muscle, 2021
Background Non‐alcoholic fatty liver (NAFL) disease (NAFLD) is the most common chronic liver disease in the world. While most subjects have ‘inert’ NAFL, a subset will progress to non‐alcoholic steatohepatitis (NASH) and its life‐threatening ...
Maxime Nachit   +7 more
doaj   +1 more source

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian   +3 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

NASH: Non-Alcoholic Steatohepatitis [PDF]

open access: yes, 2015
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis without significant intake of alcohol.
Heck, Jennifer
core  

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Home - About - Disclaimer - Privacy